Search results for: Scotland
Filter search results
Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK
14 March 2017
…that compares the availability of and access to orphan medicinal products (OMPs) in the UK (England, Scotland and Wales), France, Germany, Italy and Spain. The analysis quantifies the availability, access and the time…
How Important are the Differences Between the EQ-5D-5L and EQ-5D-3L Value Sets?
24 March 2017
…have collected in Scotland, Wales and Northern Ireland to also create a UK 5L value set. So at present a 5L value set for the UK is not available. Users…
Invitation to OHE’s Annual Lecture 2017: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe?
12 May 2017
…in Scotland and Northern Ireland and, to a lesser extent, in England and Wales over the same period. However, more robust progress against heart disease has – to date –…
OHE at HTAi 2017: Meet the Team
13 June 2017
…This study compares the availability and access to orphan medicinal products in the UK (England, Scotland and Wales), France, Germany, Italy and Spain. Orphan drugs are authorised in all EU…
OHE’s Professor Nancy Devlin Elected as ISPOR’s Incoming President
22 May 2018
…Slovenia Jalpa A. Doshi, PhD, Professor, University of Pennsylvania School of Medicine, Philadelphia, PA, USA Neil Hawkins, PHD, MBA, Professor of Health Technology, Assessment, University of Glasgow, Glasgow, Scotland, UK…
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
18 July 2018
…(England) and SMC (Scotland) regarding novel drugs approvals in our sample to collect data on patient population sizes. Although in the algebraic formulation, the authors consider a number other factors,…
“You Don’t Always Get What You Want”: Output Distortion and NHS Waiting Time Targets
18 December 2018
…that the policy worked to lower waiting times through a difference-in-difference approach comparing England (treatment) and Scotland (control) when the policy was first introduced. Generally, clear, measurable targets with hard…
Assessing Trends in SMC Advice Decisions (October 2009- September 2015)
1 February 2016
The objective of this OHE Consulting Report was to outline trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015. This report…
International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
5 January 2020
OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs). In addition to the…